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Abstract Myeloid-derived suppressor cells (MDSC) are cells
of myeloid origin with enhanced suppressive function. They
are negative regulators of the immune responses and comprise
a heterogeneous mixture of immunosuppressive cells of
monocytic (M-MDSC) and granulocytic (G-MDSC) origin.
A more recent nomenclature proposes the term Bsuppressive
monocyte derived cells^ (suppressive MCs) to define CSF1/
CSF2-dependent mouse suppressor cells that develop from
common monocyte progenitors (cMoPs) after birth. Here,
we review the literature about monocytic-derived cells with
demonstrated suppressor function in vitro and in vivo within
the context of solid organ transplantation.
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Introduction
The mononuclear phagocyte system (MPS) comprises mono-
cytes, macrophages, and dendritic cells (DCs). The terminol-
ogy to define cell subsets that belong to the MPS is currently
confusing, and a new classification of macrophages,
monocytes, and DCs was recently proposed. In mice, two
main subsets of monocytes (Ly6Chi/CX3CR1lo and Ly6Clo/
CX3CR1hi) [1]; three main subsets of DCs (BATF3 dependent
cDC1, IRF4 dependent cDC2, and E2-2 dependent pDC) [2];
and various types of tissue resident macrophages that originate
during embryogenesis (Kupffer cells—liver, microglia—
brain, Langerhans cells—epidermis, alveolar macrophages—
lung) [3] have been defined. Upon inflammation, monocytes
and DCs infiltrate the injured tissue and, along with the resi-
dent macrophages undergo activation, acquiring an inflamma-
tory phenotype. This results in an overlapping expression of
phenotypic markers, such as CD11c, F4/80, and MHC-II
among these cell subsets, which makes it difficult to charac-
terize specific myeloid cells under inflammatory conditions
[4]. In an attempt to exploit immune regulatory mechanisms
that take place during cancer progression and under other
inflammatory pathological conditions, the term myeloid-
derived suppressor cells (MDSC) was originally proposed to
describe CD11b+Gr-1+ expressing myeloid cells with the abil-
ity to suppress the immune response [5]. The terminology was
widely accepted by the research community, including trans-
plant immunologists, which reported the critical implication
of monocytic MDSC (M-MDSC) in the prolongation of allo-
graft survival. A more recent nomenclature of the MPS has
been proposed based on ontogeny, location, function, and
phenotype [2]. This latest classification provides a criterion
to define new myeloid subsets and recommends the term sup-
pressive monocyte-derived cells (suppressive MCs) as CSF1/
CSF2-dependent suppressor cells that develop from common
monocyte progenitors (cMoPs) after birth. Here, we provide a
historical overview of monocyte-derived cells with demon-
strated suppressive function in the context of solid organ
transplantation.
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Suppressive MCs in Solid Organ Transplantation
Allograft immunological unresponsiveness is associated with
presence of suppressor cells in the transplanted recipients,
which include cells of the lymphoid and the myeloid lineage
[6]. In solid organ transplantation, Nicholas Tilney and Terry
Strom first suggested the suppressive activity of graft infiltrat-
ing, monocyte-derived cells in 1977 [7]. The suppressive ca-
pacity of acute rejecting and enhanced rat cardiac allograft
infiltrating cells (in which macrophages account for 10 % of
the total) were analyzed by spontaneous blastogenesis using
3H-thymidine incorporation. Using fractionation approaches,
the authors reported that the greatest suppressive activity
corresponded to adherent cells of enhanced recipients
(90 %), in contrast to non-adherent cells obtained from
rejecting recipients (15%) [7]. Further analysis of the adherent
cells present in the spleen confirmed the above results, sug-
gesting that monocyte-derived inflammatory macrophages,
which accumulate in the enhanced allografts early after trans-
plantation, possessed suppressive function.
In 1979, seminal work fromHyungMo Lee and colleagues
reported macrophage-related suppressor cell function in hu-
man renal transplant recipients [8•]. The study delineated the
immune reactivity of cells obtained from 66 renal transplant
recipients under routine immunosuppressive therapy with
prednisone and azathioprine. The suppressive activity of
mononuclear cells from renal transplant recipients was
assayed by adding recipient mononuclear cells to donor stim-
ulated, third-party cytotoxic T lymphocytes responding
against 51Cr-labeled donor target cells. The percentage of lysis
of target cells measured by 51Cr release into the medium dem-
onstrated that addition of mononuclear cells from renal trans-
plant recipients suppressed cell-mediated lympholysis (CML)
of donor cells in vitro. As controls for the suppressive func-
tion, the authors used non-donor fourth-party stimulated cyto-
toxic T lymphocytes and non-donor (recipient or irrelevant)
51Cr-labeled target cells, showing no suppressive activity. This
experiment confirmed the antigen-specific suppressive func-
tion of transplant recipient mononuclear cells. Further, the
authors went onto demonstrate that the adherent cell fraction
of the mononuclear cells from renal transplant patients, con-
taining 54–82 % esterase positive monocytes/macrophages,
was responsible for the donor specific suppression.
Shortly afterwards, Judith and Francis Thomas extended
their findings using an experimental skin allograft transplant
model in rhesus monkey recipients that received a 5-day
course of anti-thymocyte globulin (ATG) treatment [9]. The
in vitro mitogen-induced lymphoproliferative response was
reduced by the adherent fraction of the peripheral blood
mononuclear cells (PBMC) from ATG-treated versus untreat-
ed rhesus monkeys skin allograft recipients. Both concanava-
lin A (Con A)- and phytohemagglutinin (PHA)-induced lym-
phocyte blastogenesis were reduced significantly when
prostaglandin synthetase-dependent adherent cells were added
to the cultures, suggesting that suppressive macrophages me-
diated part of the ATG induced immunosuppressive function.
These experiments confirmed in vitro previous findings
linking the immunosuppressive function of ATGwith the abil-
ity of macrophages to phagocyte lymphocytes. In 1969, Ivan
Roitt and colleagues reported that the immunosuppressive ca-
pacity of anti-lymphocyte sera (ALS) and its ability to prolong
skin graft survival was associated with the capacity of macro-
phages to opsonize lymphocytes in vitro [10]. The authors
reported that cytoadherence represented an early step in the
process of opsonization, which suggested that the immuno-
suppressive function of ALS was in part due to macrophage-
mediated in vitro lymphocyte phagocytosis [11]. Similar re-
sults associated the suppressive function anti-lymphocyte
globulin (ALG) with the rosette formation of lymphocytes
around monocytes [12].
In 1983, an elegant study from Deborah Cameron further
validated the suppressive function of macrophages present in
transplant recipients [13]. Macrophages obtained from pred-
nisone plus azathioprine treated human kidney transplant pa-
tients mediated cell cytotoxicity, as measured by release of 3H-
thymidine labeled target cells in vitro. Later in 1991, Kamada
and colleagues reported two phases of cell-mediated suppres-
sor activity, involving macrophages and regulatory T cells,
respectively, in an experimental rat liver transplant model
[14]. Early after transplantation (4–34 days), adherent sup-
pressor macrophages present in the spleen of tolerant recipi-
ents mediated the in vitro inhibitory function measured by
suppression of mixed leukocyte reactions, while late after
transplantation (20 weeks), non-adherent suppressor T cells
were responsible for the suppressive function of recipient
splenic cells. Moreover, macrophage-mediated suppression
was dependent on prostaglandins, since indomethacin
inhibited their suppressive function [14]. These results sug-
gested that non-specific suppressor macrophages develop in
the spleens of tolerant liver transplant recipients.
The first report describing the suppressive activity of
CD11b expressing monocytic cells was from by Myburgh
and colleagues in 1995 [15]. Using non-human primates treat-
ed with total lymphoid irradiation as tolerogenic therapy, the
authors characterized the antigen non-specific suppressor cells
present in renal allograft recipients that inhibited in vitro
mixed lymphocyte cultures. Depletion of CD11b or CD38
expressing cells resulted in loss of suppressive function of
mononuclear cells obtained from the blood of transplanted
baboons indicating that monocytes and NK cells mediated
inhibition of cell proliferation. Suppression was mediated by
a soluble factor, as inhibition of mixed lymphocyte cultures
(MLC) separation of suppressor macrophages from
responding T cells by a transwell cellulose membrane abro-
gated the in vitro suppressive activity. The authors went on to
demonstrate that suppression was not mediated by PGE2 or by
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de novo protein synthesis since neither indomethacin nor cy-
cloheximide had any effect on macrophage-mediated T cell
hyporesponsiveness. On the contrary, the lysosome-
destabilizing adjuvant Leu-Leu-OMe (LLOMe), which in-
duces lysosome rupture, degradation of inflammatory pro-
teins, and necrotic cell death, revealed that LLOMe treatment
abrogated the macrophage inhibitory effect.
MDSC in Solid Organ Transplantation
Using the MDSC terminology [5], Vanhove and colleagues
were the first to report the critical role of MDSC in solid organ
transplantation using an experimental kidney transplant model
in rats [16]. Tolerance was induced by a costimulatory block-
ade with anti CD28 antibodies and CD11b+CD80/86+Sirpα+
expressing MDSC cells accumulated in the recipient allo-
grafts. The CD11b+Sirpα+ expressing MDSC present in the
blood and bone marrow inhibited proliferation of anti-CD3/
CD28 stimulated Tcells in a contact-dependent manner, while
the same cells obtained from the lymph nodes or the spleen
did not. The suppressive mechanisms of tolerance was in part
mediated by the inducible nitric oxide synthase (iNOS), since
in vivo treatment with the iNOS inhibitor aminoguanidine
abrogated tolerance in long-term allograft survival recipients
(<120 days post-transplantation), and all grafts were rejected
acutely. The critical role for iNOS in MDSC-mediated T cell
suppression was reported by Segal and colleagues in experi-
ments using inducible NO synthase knockout mice, which
demonstrated that NO inhibited of T cell proliferation in an
antigen-specific and cell contact-dependent manner [17]. In a
separate report, Vanhove’s laboratory demonstrated that graft
infiltrating CD11b+CD80/86+Sirpα+ expressing MDSC were
responsible for the CCL5 gradient that directs Treg into the
tolerized allograft during the induction of kidney allograft
survival in rats [18].
In mice, MDSC express the cell surface markers CD11b
(Mac-1) and Gr-1 [19, 20], and using these markers, Horuzsko
and colleagues described a different mechanism by which
MDSC mediated prolonged allograft survival [21]. Using an
MHC-II mismatched bm12 skin transplants, which varies
from its parental strain C57BL/6 at the I-A beta locus but
are matched at all other major and minor histocompatibility
antigens, the authors demonstrated that binding of HLA-G to
the immunoglobulin-like transcript 2 (ILT-2) expressed in sup-
pressive CD11b+Gr-1+ expanded MDSC in vivo. This expan-
sion was associated to indefinite allograft survival of MHC-II
mismached skin graft recipients. The data is consistent with a
previous report from Suciu-Foca and colleagues, which re-
ported that expression of the ILT2/3 mice homologue paired
immunoglobulin-like receptor B (PIR-B) in myeloid cells as-
sociated with prolonged allograft survival a rat transplant
model [22].
Le Moine and colleagues reported the critical role of heme
oxygenase-1 (HO-1) in MDSC-mediated alloreactivity sup-
pression [23]. Using the skin transplant system described
above (bm12 MHC-II disparate skin grafts into C57BL/6 re-
cipients), the authors reported that in vivo treatment with LPS
resulted in the development of HO-1 expressing CD11b+GR-
1+ MDSC that produced large amounts of IL-10. These LPS-
induced MDSC were able to inhibit polyclonally activated
CD4+ and CD8+ T cell proliferation in an antigen-specific
dependent manner. The authors went on to demonstrate that
HO-1 inhibition abrogated and prevented IL-10 production by
MDSC. Further, they demonstrated the potential therapeutic
applications of MDSC in prolonging allograft survival using
adoptive transfer experiments. This is to our knowledge the
first report of MDSC transfer to unmanipulated recipients to
prolong graft survival. These findings are consistent with pre-
vious reports suggesting the critical role of HO-1 in the mod-
ulation of IL-10 and the promotion of tolerance to transplanted
organs. Bach and colleagues reported that, while long-term
tolerance was not achieved in HO-1 deficient recipients, in-
duction of HO-1 expression by cobalt protoporphyrin IX led
to a significant up-regulation of Foxp3, TGF-beta, IL-10, and
CTLA4 associated with prolonged graft survival [24]. Specif-
ic overexpression of HO-1 following adenovirus-mediated
(AdHO-1) gene transfer has been reported to prolong graft
survival [25].
In a mouse heart transplantationmodel under costimulatory
blockade with anti-CD40L mAb, Ochando and colleagues
demonstrated the tolerogenic role of MDSC in solid organ
transplantation [26••]. Using different depletional approaches,
including antibodies against Gr-1 and Ly6G, CD11b-DTR
mice, Macrophage Fas-Induced Apoptosis (MAFIA) mice,
and clodronate liposomes, the authors reported that transplan-
tation tolerance was dependent on CD11b+CD115+GR-1+
MDSC that migrated from the bone marrow to the transplant
organ shortly after transplantation, where they prevented the
initiation of adaptive immune responses that lead to allograft
rejection and participated in the development of Tregs. The
authors further proposed that both iNOS and arginase-1 (Arg-
1) mediated the suppressive function of monocytic
CD11b+CD115+GR-1+ suppressive cells. MDSC use these
enzymes to mediate their suppressive function, both of which
are implicated in the L-arginine metabolism: iNOS, leading to
suppressive NO production and Arg-1, which causes a direct
starvation of arginine within the microenvironment [27]. This
study is consistent with a previous report which demonstrated
that CD115 expressing MDSC induced antigen-specific Treg
expansion and iNOS dependent T cell suppression in tumor-
bearing mice [28].
Using a pancreatic islet transplantation in a diabetic mice,
Bronte and colleagues described for the first time that organ
rejection could be prevented by MDSC generated in vitro
[29••]. Using a model of subcapsular islet transplantation in
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diabetic mice, the authors demonstrated that transfer of
MDSC generated with GM-CSF and IL-6 inhibited CD8+ T
cell priming and induced long-term acceptance of allogeneic
islet allografts in the absence of immunosuppressive drug
treatment. In the GM-CSF+IL-6 induced MDSCs treatment
group, about 75 % of mice remained normoglycemic and
healthy for the entire observation period of 200 days, analo-
gously to all the control mice transplanted with syngeneic
islets. Graft histology indicated a histological pattern not com-
patible with insulitis in the MDSC-treated group and demon-
strated that the lymphocytic infiltration (comprising CD4+,
CD8+ T cells, and CD49b+ cells) was usually confined to the
areas surrounding the insulin-positive graft. Tolerance was
due the inhibition of IFN-γ production by T cells and was
dependent on the expression of CCAAT/enhancer-binding
protein β (C/EBPβ), which regulates myelopoiesis during
emergency myelopoiesis and has a crucial role in controlling
the differentiation of myeloid progenitors to MDSC. This re-
sults have been recently confirmed by Louvet and colleagues,
which evaluated the potential of GM-CSF/IL-6 and LPS-
induced MDSC to control auto- and allo-immunity [30].
Using MHC class II disparate skin allograft model,
Inverardi and colleagues demonstrated the ability of the
colony-stimulating factor 3 (CSF3) to induce IL-4Rα+MDSC
in vivo following a short course of Neupogen treatment [31].
The authors further demonstrated that Neupogen mediated
expansion of MDSC together with interleukin-2 complex
(IL-2C) mediated expansion of Treg in vivo prolong allograft
survival (MST=74 days). When looking into the mechanisms
that were responsible for prolonged allograft survival, the au-
thors indicated that synergistic treatment with Neupogen plus
IL2-C resulted in an attenuated T cell response and reduction
of cellular infiltrates into the allografts.
In addressing the involvement of alarmins in MDSC
immunobiology, Thomson and Turnquist reported the cru-
cial role for IL-33 in prolonging heart allograft survival in
mice [32]. The authors demonstrated that IL-33 induces
an increase in suppressive CD11b+Gr-1+ MDSC, together
with an expansion of suppressive ST2+Foxp3+ regulatory
T cells in an ST2 (IL-1R-like-1)-dependent-manner
in vivo. These findings revealed a new immunoregulatory
activity of IL-33 with cardioprotective properties, as it
limits ST2 expression and cardiovascular pathology. A
recent report from this group confirms the potential role
of IL-33 in the generation of activated IL-33R/
ST2+ICOShighCD44highFoxp3+ Treg [33]. In human kid-
ney transplant recipients, IL-33 represents an innate in-
flammatory mediator that activates iNK cells during is-
chemia reperfusion injury, and neutralization of IL-33
has been proposed as a potential therapeutic target [34].
These results contrast previous murine findings suggest-
ing that IL-33 increase CD11bhigh Gr-1int MDSC that
favors immune deviation, Foxp3+ Treg expansion,
reduces antibody-mediated rejection, and prolongs allo-
graft survival during acute and chronic cardiac rejection
[35, 36].
An elegant study from Zhao and colleagues elucidated part
of the signaling pathwaymediated in iNOS-dependent prolon-
gation of allograft survival mediated by MDSC [37].
CD11b+Gr-1+ myeloid cells obtained from Smad3-deficient
mice were shown to significantly inhibit alloantigen specific
Tcell responses, which resulted in a delayed allograft rejection
in both skin and heart transplantation model in mice. These
results reinforce the concept that transforming growth factor-β
(TGF-β)/Smad3 signaling plays a complex role in the im-
mune system, as TGF-β directly suppresses both the clonal
expansion of CD8+ T cells and their cell cytotoxicity in vivo
[38]. The authors further demonstrated that Smad3-deficient
MDSCwere responsible for skewing Tcells towards Th2-type
immunity in transplanted Smad3−/− mouse recipients. There-
fore, this study demonstrated that Smad3 is an intrinsic factor
that inhibits the differentiation and immunosuppressive func-
tion of CD11b+Gr-1+ MDSC in mouse transplant models.
Luo and colleagues reported that infusions of donor
splenocytes treated with 1-ethyl-3(3′-dimethylaminopropyl)-
carbodiimide (ECDI-SPs) induced permanent donor-specific
protection of islet allografts and prolonged cardiac allograft
survival associated with intragraft accumulation of
CD11b+IDO+ MDSC [39, 40]. Indoleamine 2,3 dioxygenase
(IDO) activity limits T cell growth by depleting L-tryptophan
and promotes T cell apoptosis by generating L-tryptophan-de-
rived metabolites (i.e., kynurenins). Presence of intragraft
CD11b+IDO+ population was dependent on GR-1+ cells and
either depletion of GR-1+ cells or inhibition of IDO activity
abrogated graft protection by ECDI-SPs. Additionally, the au-
thors reported that induction of tolerance is critically depen-
dent on PD1/PDL1 signaling pathway, Foxp3+ Treg, and as-
sociated with increased IL-10 levels from in vitro stimulated T
cells from ECDI-SPs treated recipients. In combination with a
short course of rapamycin (day −1 to +8) ECDI-SPs induced
long-term allograft survival (>150 days) in 100 % of the re-
cipients. These results extend previous finding demonstrating
that ECDI-fixed allogeneic splenocytes induced reduced CD8
T cell-mediated cytotoxicity in mixed lymphocyte reactions
and in vivo CD4 T cell anergy [41, 42].
Lina Lu and colleagues reported the importance of stromal
cells in the generation of graft protective MDSC [43]. Using
an islet transplant model, the authors demonstrated that trans-
fer of CD11b+ and hepatic stellate cells (HSC) into the renal
capsule of diabetic recipients differentiated CD11b+ myeloid
cells into potent MDSC that protected islet allograft and pro-
moted long-term graft survival. MDSC protected the allo-
grafts by attenuating CD8+ Tcell alloreactivity and promoting
antigen-specific Treg cell development through the B7-H1
pathway. Both in vitro and in vivo data demonstrated that
B7-H1 was required for MDSC to exert immune regulatory
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activity. The data extends previous findings from this group,
which documented the induction of MDSC by HSC [44].
HSC-induced MDSC co-transplanted into the allografts
expressed high levels of iNOS and Arg-1 and suppressed the
proliferative response of both CD4+ and CD8+ T cells. Mech-
anistically, the authors showed that HSC lost their ability to
induceMDSCwhen using HSC from IFNγR1 deficient mice,
and suggested that MDSC induction was mediated by soluble
factors produced by HSC, such as complement 3 [45]. A re-
cent report from this group reported the beneficial effects of
GM-CS and HSC in the generation of iNOS+ MDSC [46].
Strober and colleagues elucidated the cellular and molecu-
lar mechanisms by which a conditioning regimen with total
lymphoid irradiation, anti-thymocyte serum (ATS), and donor
bone marrow transplant induced the expansion of IL-4Rα
expressing MDSC that mediated the acceptance of cardiac
allografts [47]. Specifically, the authors established that this
conditioning regimen generates a tolerogenic environment
with augmented numbers of IL-4Rα expressing MDSC and
IL-4 secreting iNKT. Using iNKT-deficient (CD1day−/− and
Ja18−/−) and IL-4-deficient mice, the authors concluded that
transplantation tolerance depended on MDSC-iNKT interac-
tion and further implicated the possible role for Arg-1 in this
clinically relevant conditioning regimen with the concomitant
therapeutic applications. L-arginine is an amino acid essential
for lymphocyte growth and differentiation, and depletion of L-
arginine through Arg-1 inhibits T cell proliferation. The criti-
cal role for IL-4R expressing MDSC and Arg-1 dependent T
cell suppression was initially described by Bronte and col-
leagues, who demonstrated that arginase mediated suppres-
sion by IL-4R expressing MDSC required IL-4 [48]. These
findings are consistent with Myburgh’s report [15], which
suggested an interplay between MDSC and NK in the estab-
lishment of transplantation tolerance mediated by total lym-
phoid irradiation as induction therapy [49].
In human kidney transplant recipients, Murphy and col-
leagues reported for the first time that CD11b+CD33+HLA-
DR−MDSC were capable of expanding Treg in vitro and their
accumulation after transplantation correlated with an increase
in Treg in vivo [50•]. MDSC-dependent expansion of Treg was
suggested to be mediated by the production of soluble factors
such as TGFβ and IL10. Consistent with this hypothesis, it has
been reported that human CD14+HLA−DRlow/− MDSCs favor
the development of Foxp3+ Treg through the production of
TGFβ [51]. Interestingly, kidney transplant recipients of this
study were treatedwith the synthetic corticosteroid prednisone.
Glucocorticoids are given routinely to transplant recipient pa-
tients and induce IL-10 expression in CD11b+Gr-1+ MDSC
[52]. A recent report in mice by Liu and colleagues confirmed
the above results and extended Sunderkoetter’s findings to
demonstrate that dexamethasone induced MDSC prolong skin
allograft survival though glucocorticoid receptor, IL-10 and
iNOS dependent manner [49, 53].
Conclusions
One of the major goals in solid organ transplantation is the
induction of long-term allograft survival in a mature immune
system that is free from chronic rejection and lifelong treat-
ment with immunosuppressive drugs and their side effects.
The use of MDSC in transplantation therapy is moving for-
ward, and current literature indicates that MDSC favor allo-
graft tolerance in many ways (Fig. 1 highlights MDSC-
dependent suppressive mechanisms that mediate graft surviv-
al). MDSC suppress inflammation and promote tissue repair
in the allografts, exert immunosuppressive effects by secreting
anti-inflammatory mediators, and induce alloantigen-specific
Tregs, anergizing, and/or depleting recipient effector T cells.
However, the complexity of the in vivo myeloid system in
solid organ transplantation that regulates the immune response
during strong sterile inflammatory conditions due to ischemia
reperfusion injury of the donor organ and surgical anastomosis
in the recipient makes it difficult to determine the specific
mechanisms by which myeloid-derived subsets exert their in-
hibitory function. The original MDSC terminology includes
multiple cell subsets as myelopoiesis refers to the differentia-
tion of a myeloid progenitor into granulocytes, macrophages,
mast cells, and dendritic cells. Myeloid cell subsets have been
historically proposed based on morphology, cytochemistry,
and flow cytometry, but the latest technological revolution in
deep-sequencing, mass cytometry, and fate mapping experi-
ments in vivo will enable us to classify myeloid cell subsets
more appropriately. Using some of these novel approaches,
Guilliams and collaborators have proposed the term
monocyte-derived suppressive cells [2]. This recent classifica-
tion may be more comprehensive in solid organ transplanta-
tion as it would include seminal studies from different labora-
tories that investigated the suppressive function of monocyte-
derived cells. Hutchinson and colleagues reported the thera-
peutic potential of regulatory macrophages in human kidney
transplant recipients and cardiac allograft transplanted mice
Fig. 1 Monocyte-derived suppressor cells in transplantation. The figure
summarizes induction therapies and mechanisms of action of monocyte-
derived suppressor cells in organ transplantation. GR glucocorticoid re-
ceptor, PR phagocytic receptor, TLI/ALS total lymphoid irradiation/anti-
thymocyte serum
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([54•], [55••]), and Burlingham and colleagues reported graft
survival prolongation using Lacto-N-fucopentaose III activat-
ed macrophages [56]. On the other hand, and in contrast to G-
MDSC depletional studies in tumor bearing mice [57], we
demonstrated that depletion of Ly6G expressing granulocytic
cells (clone A18) had no effect in tolerance, suggesting that
only monocyte-derived cells are responsible for the induction
of indefinite allograft survival in solid organ transplantation.
In conclusion, clarification on how suppressive cells of the
mononuclear phagocyte system are classified, consensus on
which markers should be used for subset identification, and
unified guidelines to characterize future suppressive cell sub-
sets in solid organ transplantation is urgently needed.
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